Skip to main content

Table 4 Prediction for mortality

From: One-year mortality and Periprosthetic infection rates after Total knee Arthroplasty in Cancer patients: a population-based cohort study

  Adjusted
sHRa(95%C.I.) p-value
Cancer vs. Non-cancer 2.46 (1.71–3.52) <.0001
Comorbidities
 Myocardial infarct 1.98 (0.98–3.99) 0.0557
 congestive heart failure 1.56 (0.98–2.49) 0.0632
 peripheral vascular 0.53 (0.17–1.64) 0.2717
 cerebrovascular disease 0.83 (0.57–1.20) 0.3263
 dementia 0.97 (0.40–2.34) 0.9477
 chronic lung disease 1.26 (0.74–2.17) 0.3943
 connective tissue disease 1.23 (0.65–2.32) 0.5240
 Ulcer 1.31 (0.67–2.56) 0.4305
 chronic liver disease 1.43 (0.32–6.48) 0.6403
 Diabetes 1.04 (0.67–1.63) 0.8608
 diabetes with end organ damage 1.24 (0.55–2.79) 0.5993
 Hemiplegia 1.80 (0.52–6.24) 0.3566
 moderate or severe kidney disease 1.84 (0.64–5.32) 0.2614
 Moderate or severe liver disease  
 AIDS  
Metastasis 1.17 (0.68–2.01) 0.5754
  
  1. sHRa: subdistribution hazard ratio